Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 2
1984 2
1986 1
1987 1
1988 2
1989 5
1990 5
1991 1
1992 11
1993 9
1994 4
1995 7
1996 9
1997 8
1998 16
1999 3
2000 11
2001 7
2002 3
2003 7
2004 8
2005 12
2006 14
2007 16
2008 15
2009 18
2010 9
2011 20
2012 20
2013 13
2014 21
2015 11
2016 13
2017 5
2018 13
2019 14
2020 9
2021 8
2022 14
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

341 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.
Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M, van Hall T, Ossendorp F. Fransen MF, et al. Among authors: camps mg. JCI Insight. 2018 Dec 6;3(23):e124507. doi: 10.1172/jci.insight.124507. JCI Insight. 2018. PMID: 30518694 Free PMC article.
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways.
López-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, Beretta L, Simeón CP, Carreira P, Ortego-Centeno N, Castellvi I, Bossini-Castillo L, Carmona FD, Orozco G, Hunzelmann N, Distler JHW, Franke A, Lunardi C, Moroncini G, Gabrielli A, de Vries-Bouwstra J, Wijmenga C, Koeleman BPC, Nordin A, Padyukov L, Hoffmann-Vold AM, Lie B; European Scleroderma Group†; Proudman S, Stevens W, Nikpour M; Australian Scleroderma Interest Group (ASIG); Vyse T, Herrick AL, Worthington J, Denton CP, Allanore Y, Brown MA, Radstake TRDJ, Fonseca C, Chang HY, Mayes MD, Martin J. López-Isac E, et al. Nat Commun. 2019 Oct 31;10(1):4955. doi: 10.1038/s41467-019-12760-y. Nat Commun. 2019. PMID: 31672989 Free PMC article.
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.
Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Roch B, Fernández-Nebro A, Boffa MC, Hughes GR, Ingelmo M; Euro-Phospholipid Project Group. Cervera R, et al. Among authors: camps mt. Arthritis Rheum. 2002 Apr;46(4):1019-27. doi: 10.1002/art.10187. Arthritis Rheum. 2002. PMID: 11953980 Free article.
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.
Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, Buonaiuto V, Jacobsen S, Zeher MM, Tarr T, Tincani A, Taglietti M, Theodossiades G, Nomikou E, Galeazzi M, Bellisai F, Meroni PL, Derksen RH, de Groot PG, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Fernández-Nebro A, Haro M, Amoura Z, Miyara M, Tektonidou M, Espinosa G, Bertolaccini ML, Khamashta MA; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Cervera R, et al. Ann Rheum Dis. 2015 Jun;74(6):1011-8. doi: 10.1136/annrheumdis-2013-204838. Epub 2014 Jan 24. Ann Rheum Dis. 2015. PMID: 24464962 Free article.
Biologics-induced autoimmune diseases.
Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Perez-Alvarez R, et al. Curr Opin Rheumatol. 2013 Jan;25(1):56-64. doi: 10.1097/BOR.0b013e32835b1366. Curr Opin Rheumatol. 2013. PMID: 23114587 Review.
Mechanisms of Theta Plasmid Replication.
Lilly J, Camps M. Lilly J, et al. Among authors: camps m. Microbiol Spectr. 2015 Feb;3(1):PLAS-0029-2014. doi: 10.1128/microbiolspec.PLAS-0029-2014. Microbiol Spectr. 2015. PMID: 26104556 Free article. Review.
OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.
van der Sluis TC, Beyrend G, van der Gracht ETI, Abdelaal T, Jochems SP, Belderbos RA, Wesselink TH, van Duikeren S, van Haften FJ, Redeker A, Ouboter LF, Beyranvand Nejad E, Camps M, Franken KLMC, Linssen MM, Hohenstein P, de Miranda NFCC, Mei H, Bins AD, Haanen JBAG, Aerts JG, Ossendorp F, Arens R. van der Sluis TC, et al. Among authors: camps m. Cell Rep Med. 2023 Mar 21;4(3):100939. doi: 10.1016/j.xcrm.2023.100939. Epub 2023 Feb 15. Cell Rep Med. 2023. PMID: 36796366 Free PMC article.
Genetic constraints on protein evolution.
Camps M, Herman A, Loh E, Loeb LA. Camps M, et al. Crit Rev Biochem Mol Biol. 2007 Sep-Oct;42(5):313-26. doi: 10.1080/10409230701597642. Crit Rev Biochem Mol Biol. 2007. PMID: 17917869 Free PMC article. Review.
341 results